EUVIMEDEUVIMED entdecken
Crossref

Impact of ABO Blood Group on Thromboembolic and Bleeding Complications in Patients with Left Ventricular Assist Devices

Maximilian Tscharre iD, Franziska Wittmann, Daniela Kitzmantl, Thomas Schlöglhofer, Philip Cichra, Silvia Lee, Beate Eichelberger, Patricia P Wadowski, Günther Laufer, Dominik Wiedemann, Simon Panzer, Daniel Zimpfer und 1 weitere

Thrombosis and Haemostasis · 01.03.2023 · 123 (03) · 336-346

DOI: 10.1055/a-1983-0676 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.03.2023. Verfasst von Maximilian Tscharre und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Cardiology and Nephrology, Landesklinikum Wiener Neustadt, Wiener Neustadt, Austria. Hauptthemen laut MEDLINE: Heart-Assist Devices, Thromboembolism, Hemostatics, von Willebrand Diseases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Wellcome Trust, Austrian Heart Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The ABO blood group system is linked to hemostasis via its relationship with von Willebrand factor (VWF) and factor VIII (FVIII). In the current study, we investigated the association of the ABO system with clinical outcomes as well as VWF and platelet function in patients with left ventricular assist devices (LVADs).

Methods

Bleeding and thromboembolic complications were assessed in 111 patients during 1 year after LVAD implantation. In 67 LVAD patients, VWF antigen, VWF activity, VWF ristocetin cofactor, VWF collagen-binding, and FVIII activity were assessed. Platelet surface P-selectin and activated glycoprotein IIb/IIIa were determined by flow cytometry, and soluble P-selectin was measured with an enzyme-linked immunoassay. Platelet aggregation was assessed by light transmission and impedance aggregometry.

Results

Thirty-six patients (32.4%) experienced a bleeding and 22 patients (19.8%) a thromboembolic event. In univariate analyses, patients with blood group O had numerically more bleeding complications and less thromboembolic events as compared to patients with blood group non-O (both p ≥ 0.05). After multivariable adjustment, blood group O was significantly associated with a higher risk of bleeding (hazard ratio 2.42 [95% confidence interval 1.03–5.70], p = 0.044) but not linked to thromboembolic complications.

Conclusion

Patients with blood group O had significantly lower levels of VWF and FVIII (all p < 0.05), whereas P-selectin expression in response to thrombin-receptor activating peptide and soluble P-selectin were higher as compared to patients with blood group non-O (both p < 0.05). LVAD patients with blood group O are at an increased bleeding risk, potentially due to lower VWF and FVIII levels.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart-Assist DevicesThromboembolismHemostaticsvon Willebrand DiseasesHumansvon Willebrand FactorABO Blood-Group SystemP-SelectinFactor VIIIHemorrhage

Substanzen

von Willebrand FactorABO Blood-Group SystemP-SelectinFactor VIIIHemostatics

Autor:innen und Institutionen

  • Department of Internal Medicine, Cardiology and Nephrology, Landesklinikum Wiener Neustadt, Wiener Neustadt, Austria.
  • Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
  • Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria.
  • Department of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria.
  • Department of Internal Medicine I, Cardiology and Intensive Care Medicine, Landesklinikum Mistelbach-Gänserndorf, Mistelbach, Austria.
  • Institute of Cardiovascular Pharmacotherapy and Interventional Cardiology, Karl Landsteiner Society, St. Pölten, Austria.

ORCID-Profile: Maximilian Tscharre

Förderung

  • Wellcome Trust
  • Austrian Heart Fund

Zitieren

APA

Tscharre, M., Wittmann, F., Kitzmantl, D., Schlöglhofer, T., Cichra, P., Lee, S., Eichelberger, B., Wadowski, P. P., Laufer, G., Wiedemann, D., Panzer, S., Zimpfer, D., & Gremmel, T. (2023). Impact of ABO Blood Group on Thromboembolic and Bleeding Complications in Patients with Left Ventricular Assist Devices. Thrombosis and Haemostasis, 123(03), 336-346. https://doi.org/10.1055/a-1983-0676

Vancouver

Tscharre M, Wittmann F, Kitzmantl D, Schlöglhofer T, Cichra P, Lee S, et al. Impact of ABO Blood Group on Thromboembolic and Bleeding Complications in Patients with Left Ventricular Assist Devices. Thrombosis and Haemostasis. 2023;123(03):336-346. doi:10.1055/a-1983-0676

BibTeX
@article{Tscharre2023,
  author = {Tscharre, Maximilian and Wittmann, Franziska and Kitzmantl, Daniela and Schlöglhofer, Thomas and Cichra, Philip and Lee, Silvia and Eichelberger, Beate and Wadowski, Patricia P and Laufer, Günther and Wiedemann, Dominik and Panzer, Simon and Zimpfer, Daniel and Gremmel, Thomas},
  title = {Impact of ABO Blood Group on Thromboembolic and Bleeding Complications in Patients with Left Ventricular Assist Devices},
  journal = {Thrombosis and Haemostasis},
  year = {2023},
  volume = {123},
  number = {03},
  pages = {336--346},
  doi = {10.1055/a-1983-0676}
}
Kostenlos starten →